NCT04300517

Brief Summary

Protein intake in spinal fusion surgery can prevent paraspinal muscle atrophy by maintaining muscle mass, regeneration, and growth. Also, by reducing the amount of pseudarthrosis, pain and disability can have a positive effect on recovery. The high prevalence of this type of surgery, the instability and degeneration of adjacent surfaces of fused sections, lumbar muscle atrophy, increased muscle tissue fat, and negative impact on patient recovery, also with regard to the fact that research has so far aimed to determine The effect of protein supplementation on para-spinal muscles has not been studied in patients undergoing posterior lumbar spine fusion surgery, therefore clinical trials are necessary. In this trial patients undergoing elective posterior spine fusion surgery are divided into two groups of intervention or control.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Feb 2020

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2020

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

March 3, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 9, 2020

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2020

Completed
Last Updated

July 28, 2020

Status Verified

July 1, 2020

Enrollment Period

5 months

First QC Date

March 3, 2020

Last Update Submit

July 25, 2020

Conditions

Keywords

Protein supplementSpine SurgeryParaspinal Muscles

Outcome Measures

Primary Outcomes (1)

  • The thickness of the paraspinal muscles in CT scan

    The thickness of the paraspinal muscles (multifidus, erector spinae, Quadratus, and Lumborum) in CT scan

    3 months after surgery

Secondary Outcomes (1)

  • Degree and severity of paraspinal muscle mass atrophy in CT scan

    baseline, and 3 months after surgery

Study Arms (2)

protein supplement

EXPERIMENTAL

Intervention patients will be received protein diet (1.2 g/kg/day) and protein supplement (36 g/day) for 1 month after surgery.

Drug: Three sachet of protein supplement to be mixed in with water used daily

maltodextrin

PLACEBO COMPARATOR

Control patients will be received protein diet (1.2 g/kg/day) and maltodextrin for 1 month after surgery.

Drug: Three sachet of protein supplement to be mixed in with water used daily

Interventions

Three sachet of protein supplement to be mixed in with water used daily

Also known as: Pure-protein®
maltodextrinprotein supplement

Eligibility Criteria

Age18 Years - 65 Years
Sexall(Gender-based eligibility)
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult patients 18-65 years
  • Body mass index 18.5-30
  • Candidate for the elective posterior spine fusion
  • Without history of severe liver disorder
  • Without history of Kidney disorder
  • Without history of diabetes
  • Without history of trauma and fracture of the vertebral
  • Without history of osteoporosis
  • Without history of Gastrointestinal malabsorption
  • Without history of Parathyroid gland disorders
  • Without taking medications that affect the metabolism of bone, such as calcitonin, bisphosphonate, corticosteroid
  • No smoking
  • Without history of neuromuscular diseases such as dystrophies and neurological disorders

You may not qualify if:

  • Allergy or intolerance to protein or maltodextrine supplement
  • Unwillingness to continue cooperation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Shohada Tajrish Hospital

Tehran, Iran

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

March 3, 2020

First Posted

March 9, 2020

Study Start

February 1, 2020

Primary Completion

July 1, 2020

Study Completion

July 1, 2020

Last Updated

July 28, 2020

Record last verified: 2020-07

Locations